Tandem Diabetes (TNDM) announced an agreement to develop and commercialize integrated diabetes solutions that combine Abbott’s (ABT) future dual glucose-ketone sensor with Tandem’s innovative insulin delivery systems to provide more options for people to manage their diabetes. The Abbott sensor, currently under development, will combine glucose and ketone sensing technology that aims to help people living with diabetes detect early ketone rise to avoid life-threatening diabetic ketoacidosis.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TNDM:
- Tandem Diabetes Care: Strategic Initiatives and Product Launches Drive Long-Term Growth Potential
- Balanced Outlook on Tandem Diabetes Care: Growth Opportunities Amid Strategic Challenges
- Tandem Diabetes Care Settles Patent Disputes with Roche
- Tandem Diabetes, Roche enter patent settlement agreement
- Citi ups Tandem target, adds ‘upside 90-day short-term view’